1
|
Karaca F, Keskin S, Menteş S, Boğa Z, Çavuş G, Köksal F. Evaluating interleukin-16 expression in patients with grade-3 and grade-4 glial cell tumors and healthy individuals. Niger J Clin Pract 2023; 26:1456-1462. [PMID: 37929521 DOI: 10.4103/njcp.njcp_800_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2023]
Abstract
Background This study evaluated the change in IL-16 levels in patients with high-grade glial tumors undergoing radiotherapy (RT) and healthy individuals (control group). Materials and Methods Serum IL-16 levels of 35 high-grade glioma patients receiving radiotherapy (RT) and 30 healthy individuals were compared. We compared the IL-16 levels before (RT0) and after the (RT1) and IL-16 levels were measured and the relationship of this change with other characteristics such as age, gender, weight, height, and blood test results. Results The RT0-IL-16 level was approximately 15 pg/ml higher than the RT1 measurement in the patient group. The mean RT0-IL-16 levels in the patient group were approximately 10 pg/ml higher than the mean IL-16 levels in the control group. Likewise, at the RT1 time-point, the mean IL-16 levels for the patient group were approximately 5 pg/ml lower than the mean IL-16 for the control group. The mean RT0-RT1-IL-16 value tended to be higher in female patients than in male patients. Conclusion The application of RT reduces the overall IL-16 levels, suggesting the efficacy of RT, as well as the role of IL-16 in tumorigenesis.
Collapse
Affiliation(s)
- F Karaca
- Department of Radiation Oncology, Adana City Training and Research Hospital, Adana, Turkey
| | - S Keskin
- Department of Biostatistics, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey
| | - S Menteş
- Department of Radiation Oncology, Adana City Training and Research Hospital, Adana, Turkey
| | - Z Boğa
- Department of Neurosurgery, Adana City Training and Research Hospital, Adana, Turkey
| | - G Çavuş
- Department of Neurosurgery, Adana City Training and Research Hospital, Adana, Turkey
| | - F Köksal
- Department of Microbiology, Çukurova University School of Medicine, Adana, Turkey
| |
Collapse
|
2
|
Goihl A, Rolle A, Kähne T, Reinhold A, Wrenger S, Reinhold D. Methodologic issues in the measurement of interleukin-16 in clinical blood samples using immunoassays. Cytokine 2012; 58:1-5. [DOI: 10.1016/j.cyto.2011.12.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 11/03/2011] [Accepted: 12/18/2011] [Indexed: 11/19/2022]
|
3
|
Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz) 2007; 55:41-7. [PMID: 17221335 PMCID: PMC3234149 DOI: 10.1007/s00005-007-0003-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2006] [Accepted: 10/06/2006] [Indexed: 12/21/2022]
Abstract
Introduction Macrophages/microglial cells are considered as immune cells in the central nervous system. Interleukin (IL)-16 is a proinflammatory cytokine produced by activated monocytic cells. Materials and Methods Expression of IL-16 was analyzed by immunohistochemistry in human astrocytic brain tumors and the rat C6 glioblastoma tumor model. IL-16 was detected in both human astrocytic brain tumors and rat C6 glioma. Results Compared with human control brains, a significant increase in the percentages of parenchymal IL-16+ macrophages/microglia was observed already in grade II astrocytomas, indicating that IL-16+ immunostaining could be a descriptor of a macrophage/microglia subset in astrocytic brain tumors. A further increase was observed at the transition from grade II to III astrocytomas. This increase in IL-16 immunoreactivity correlated with WHO grades of human astrocytic brain tumors. Conclusions Therefore, IL-16 might be a so far unknown factor in the regulation of the local inflammatory milieu of human and experimental astrocytomas.
Collapse
Affiliation(s)
- Markus Liebrich
- Institute of Brain Research, University of Tuebingen, Medical School, Calwerstr. 3, D-72076 Tuebingen, Germany
| | - Liang-Hao Guo
- Institute of Brain Research, University of Tuebingen, Medical School, Calwerstr. 3, D-72076 Tuebingen, Germany
| | - Hermann J. Schluesener
- Institute of Brain Research, University of Tuebingen, Medical School, Calwerstr. 3, D-72076 Tuebingen, Germany
| | - Jan M. Schwab
- Institute of Brain Research, University of Tuebingen, Medical School, Calwerstr. 3, D-72076 Tuebingen, Germany
- Equipe Developpment Neuronal, CNRS UMR 7102 Université Pierre et Marie Curie, 9 Quai Saint Bernard, 75005 Paris, France
- Center for Experimental Therapeutics, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Thorn Building for Medical Research 724, Boston, MA 02115 USA
| | - Klaus Dietz
- Department of Medical Biometry, University of Tuebingen, Medical School, Tuebingen, Germany
| | - Bernd E. Will
- Department of Neurosurgery, University of Tuebingen, Medical School, Tuebingen, Germany
| | - Richard Meyermann
- Institute of Brain Research, University of Tuebingen, Medical School, Calwerstr. 3, D-72076 Tuebingen, Germany
| |
Collapse
|
4
|
Abstract
Interleukin 16 (IL-16) has been shown to function as chemoattractant factor, as a modulator of T-cell activation and as an inhibitor of human immunodeficiency virus (HIV) replication. It is now clear that IL-16 is synthesised as a large precursor molecule (pro-IL-16), from which as yet unidentified proteases release a bioactive carboxyterminal fragment. The mechanism for IL-16 secretion is still unknown, but it is likely that the secreted protein is smaller than the originally published 130 amino acids. Upon transfection of an IL-16 cDNA, human T-cells became virtually resistant against HIV infection. This system may well be helpful in studying the mechanism of HIV suppression by this lymphokine. In addition, this approach could potentially be important for the development of gene therapy against HIV.
Collapse
Affiliation(s)
- M Baier
- Paul-Ehrlich-Institute, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
| | | |
Collapse
|
5
|
Schwab JM, Nguyen TD, Meyermann R, Schluesener HJ. Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J Neuroimmunol 2001; 114:232-41. [PMID: 11240037 DOI: 10.1016/s0165-5728(00)00433-1] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Focal cerebral ischemia elicits a strong inflammatory response which readily participates in lipid oxygenation, edema formation, apoptotic cell death and tissue remodeling. Within these conditions, cytokines are key players of cell activation and are crucial for delayed mechanisms of ischemic damage. Mature IL-16 is an immunomodulatory cytokine, exerting CD4 dependent and independent effects and is characterized by chemotactic activity, induction of early gene phosphorylation, stimulation of pro-inflammatory IL-1beta, IL-6, TNFalpha expression in monocytic cells and also modulates apoptosis. We have now analyzed expression of IL-16 in 20 brains of patients following focal cerebral infarctions (FCI, n=20). Compared to normal control brains (n=3), IL-16 was expressed by infiltrating immune cells such as neutrophils, CD8+ lymphocytes and activated CD68+ microglia/macrophages accumulating in lesion associated reactive zones and in peri-vascular regions. IL-16+ cells accumulated significantly (P<0.0001) in the necrotic lesion and at bordering peri-lesional areas at day 1-2 reaching maximum levels at day 3-4 (P<0.0001). Also, peri-vascular IL-16+ cells reached maximum levels at day 3-4 (P<0.0001) following infarction and decreased after several weeks. During the early microglial activation period, IL-16+ microglia/macrophages coexpress the activation antigen MRP-8. The accumulation of IL-16+ granulocytes, IL-16+, CD8+ lymphocytes and activated IL-16+, CD68+, CD4- microglia/macrophages, early after infarction suggest a CD4 independent, paracrine role of IL-16 in the postinjury inflammatory response, such as recruitment and activation of immune cells leading to microvessel clustering and blood-brain barrier disturbance resulting in secondary damage.
Collapse
Affiliation(s)
- J M Schwab
- Institute of Brain Research, University of Tuebingen, Medical School, Calwer Str. 3, D-72076 Tuebingen, Germany.
| | | | | | | |
Collapse
|
6
|
Zhou P, Devadas K, Tewari D, Jegorow A, Notkins AL. Processing, Secretion, and Anti-HIV-1 Activity of IL-16 With or Without a Signal Peptide in CD4+ T Cells. The Journal of Immunology 1999. [DOI: 10.4049/jimmunol.163.2.906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
CD4+ T cells transfected with the C-terminal 130 aa of human IL-16 are rendered resistant to HIV infection. Whether the constitutively expressed IL-16 acts intracellularly, extracellularly, or both is not clear. To address this question and to further study the processing of IL-16, new constructs containing either the C-terminal 130 aa or the C-terminal 100 aa (PDZ-like motif) were constructed with and without a signal peptide. Pulse-chase experiments and treatment of cells with brefeldin A and/or tunicamycin showed that IL-16 is secreted despite the absence of a signal peptide, but with a signal peptide IL-16 is processed through the endoplasmic reticulum-golgi pathway and is glycosylated. Cells expressing IL-16 linked to a signal peptide secrete considerably more IL-16 into the supernatant than cells expressing IL-16 without a signal peptide and are considerably more resistant to HIV replication. Resistance extends to almost 25 days for cells expressing IL-16 with signal peptide as compared with only 15 days for cells without signal peptide. Cells expressing the C-terminal 100 aa not linked to a signal peptide are poor secretors of IL-16 and show little if any resistance to HIV. In contrast, cells expressing the C-terminal 100 aa linked to a signal peptide secrete IL-16 and are resistant to HIV replication. It is concluded that the secretion of IL-16 is required for HIV inhibition.
Collapse
Affiliation(s)
- Paul Zhou
- Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
| | - Krishnakumar Devadas
- Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
| | - Deepanker Tewari
- Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
| | - Aleksandra Jegorow
- Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
| | - Abner Louis Notkins
- Experimental Medicine Section, Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892
| |
Collapse
|
7
|
Bannert N, Avots A, Baier M, Serfling E, Kurth R. GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes. Proc Natl Acad Sci U S A 1999; 96:1541-6. [PMID: 9990060 PMCID: PMC15509 DOI: 10.1073/pnas.96.4.1541] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Interleukin 16 (IL-16) is a chemotactic cytokine that binds to the CD4 receptor and affects the activation of T cells and replication of HIV. It is expressed as a large 67-kDa precursor protein (pro-IL-16) in lymphocytes, macrophages, and mast cells, as well as in airway epithelial cells from asthmatics after challenge with allergen. This pro-IL-16 is subsequently processed to the mature cytokine of 13 kDa. To study the expression of IL-16 at the transcriptional level, we cloned the human chromosomal IL-16 gene and analyzed its promoter. The human IL-16 gene consists of seven exons and six introns. The 5' sequences up to nucleotide -120 of the human and murine IL-16 genes share >84% sequence homology and harbor promoter elements for constitutive and inducible transcription in T cells. Although both promoters lack any TATA box, they contain two CAAT box-like motifs and three binding sites of GA-binding protein (GABP) transcription factors. Two of these motifs are part of a highly conserved and inducible dyad symmetry element shown previously to control a remote IL-2 enhancer and the CD18 promoter. In concert with the coactivator CREB binding protein/p300, which interacts with GABPalpha, the binding of GABPalpha and -beta to the dyad symmetry element controls the induction of IL-16 promoter in T cells. Supplementing the data on the processing of pro-IL-16, our results indicate the complexity of IL-16 expression, which is tightly controlled at the transcriptional and posttranslational levels in T lymphocytes.
Collapse
Affiliation(s)
- N Bannert
- Paul-Ehrlich-Institute, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
| | | | | | | | | |
Collapse
|
8
|
Abstract
CC chemokines produced by CD8(+) T cells are known to act as HIV-suppressive factors. We studied the possible role of these chemokines in HIV-1-specific killing of target cells. We found that the activity of cytotoxic T lymphocytes (CTLs) in CTL lines or freshly isolated peripheral blood mononuclear cells from HIV-1-infected individuals is markedly enhanced by RANTES (regulated on activation, normal T cell expressed and secreted) and virtually abolished by an antibody neutralizing RANTES or the RANTES receptor antagonist RANTES(9-68). Lysis was mediated by CD8(+) major histocompatibility complex class I-restricted T cells and was obtained with target cells expressing epitopes of the HIV-1LAI proteins Gag, Pol, Env, and Nef. The cytolytic activity observed in the presence or absence of added RANTES could be abolished by pretreatment of the CTLs with pertussis toxin, indicating that the effect is mediated by a G protein-coupled receptor. The chemokines monocyte chemotactic protein (MCP)-3, MCP-4, and eotaxin acted like RANTES, whereas macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, MCP-1, and stromal cell-derived factor 1 were inactive, suggesting a role for the eotaxin receptor, CCR3, and ruling out the involvement of CCR1, CCR2, CCR5, and CXCR4. CTL activity was abrogated by an antibody that blocks CCR3, further indicating that specific lysis is triggered via this chemokine receptor. These observations reveal a novel mechanism for the induction of HIV-1-specific cytotoxicity that depends on RANTES acting via CCR3.
Collapse
Affiliation(s)
- F Hadida
- Laboratoire d'Immunologie Cellulaire, Unité de Recherche Associée, Centre National de la Recherche Scientifique 625, Bâtiment Centre d'Etudes et de Recherches en Virologie et Immunologie, Hôpital Pitié-Salpétrière, 75013 Paris, France
| | | | | | | | | | | |
Collapse
|
9
|
Mühlhahn P, Zweckstetter M, Georgescu J, Ciosto C, Renner C, Lanzendörfer M, Lang K, Ambrosius D, Baier M, Kurth R, Holak TA. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat Struct Biol 1998; 5:682-6. [PMID: 9699630 DOI: 10.1038/1376] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The structure of a folded core of IL-16 is similar to that of intracellular protein modules called PDZ domains. IL-16 is thus the first extracellular protein found to have a PDZ-like fold. However, it does not exhibit normal peptide binding properties of PDZ domains. This is due to alterations of the structure at the 'PDZ-like binding site' of IL-16 (the GLGF cleft): the GLGF cleft of IL-16 is much smaller than those of PDZ-domains and is additionally blocked with a tryptophan side chain at its center. Our experiments indicate also that IL-16 nonspecifically aggregates in solution; but formation of a homo-tetrameric protein is not required, in contrast to previous suggestions, for its chemo-attractant activity.
Collapse
Affiliation(s)
- P Mühlhahn
- Max Planck Institute for Biochemistry, Martinsried, F.R.G., Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Keane J, Nicoll J, Kim S, Wu DMH, Cruikshank WW, Brazer W, Natke B, Zhang Y, Center DM, Kornfeld H. Conservation of Structure and Function Between Human and Murine IL-16. The Journal of Immunology 1998. [DOI: 10.4049/jimmunol.160.12.5945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
IL-16 is a proinflammatory cytokine that signals via CD4, inducing chemotactic and immunomodulatory responses of CD4+ lymphocytes, monocytes, and eosinophils. Comparative analysis of murine and human IL-16 homologs could reveal conserved structures that would help to identify key functional regions of these cytokines. To that end, we cloned the murine IL-16 cDNA and found a high degree of amino acid similarity comparing the predicted murine and human IL-16 precursor proteins (pro-IL-16). The highest similarity (82.1%) was found in the C-terminal region, which is cleaved from pro-IL-16 to yield biologically active IL-16. Chemotaxis experiments with IL-16 of murine and human origin, using murine splenocytes or human T lymphocytes as targets, showed cross-species stimulation of motility. Synthetic oligopeptides and anti-peptide Ab were produced, based on the sequences of three predicted hydrophilic domains of IL-16 potentially presented in exposed positions. None of these peptides had intrinsic IL-16 bioactivity, but one (corresponding to a hydrophilic C-terminal domain of IL-16) partially displaced binding of OKT4 mAb to human lymphocytes. This peptide, and its cognate Ab, also inhibited IL-16 chemoattractant activity for human and murine cells. These studies demonstrate a high degree of structural and functional similarity between human and murine IL-16 and suggest that amino acids in the C terminus are critical for its chemoattractant function. The data suggest cross-species conservation of IL-16 receptor structures as well. Inhibitory peptides may be useful in disease states where the proinflammatory functions of IL-16 are detrimental to the host.
Collapse
Affiliation(s)
- Joseph Keane
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - John Nicoll
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - Sue Kim
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - David M. H. Wu
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | | | - William Brazer
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - Barbara Natke
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - Yujun Zhang
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - David M. Center
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| | - Hardy Kornfeld
- The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
| |
Collapse
|
11
|
van Huizen R, Miller K, Chen DM, Li Y, Lai ZC, Raab RW, Stark WS, Shortridge RD, Li M. Two distantly positioned PDZ domains mediate multivalent INAD-phospholipase C interactions essential for G protein-coupled signaling. EMBO J 1998; 17:2285-97. [PMID: 9545241 PMCID: PMC1170572 DOI: 10.1093/emboj/17.8.2285] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Drosophila INAD, which contains five tandem protein interaction PDZ domains, plays an important role in the G protein-coupled visual signal transduction. Mutations in InaD alleles display mislocalization of signaling molecules of phototransduction which include the essential effector, phospholipase C-beta (PLC-beta), which is also known as NORPA. The molecular and biochemical details of this functional link are unknown. We report that INAD directly binds to NORPA via two terminally positioned PDZ1 and PDZ5 domains. PDZ1 binds to the C-terminus of NORPA, while PDZ5 binds to an internal region overlapping with the G box-homology region (a putative G protein-interacting site). The NORPA proteins lacking binding sites, which display normal basal PLC activity, can no longer associate with INAD in vivo. These truncations cause significant reduction of NORPA protein expression in rhabdomeres and severe defects in phototransduction. Thus, the two terminal PDZ domains of INAD, through intermolecular and/or intramolecular interactions, are brought into proximity in vivo. Such domain organization allows for the multivalent INAD-NORPA interactions which are essential for G protein-coupled phototransduction.
Collapse
Affiliation(s)
- R van Huizen
- Departments of Physiology and Neuroscience, The Johns Hopkins University School of Medicine, 725 N.Wolfe Street, WBSB 216, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Interleukin-16, a proinflammatory cytokine produced in CD8(+) lymphocytes, is synthesized as a precursor protein (pro-IL-16). It is postulated that the C-terminal region of pro-IL-16 is cleaved, releasing bioactive IL-16. To characterize IL-16 cleavage, we transfected COS cells with a cDNA encoding a approximately 50-kDa form of pro-IL-16. Transfected COS cells released a approximately 20-kDa IL-16 cleavage product shown to consist of the 121 C-terminal residues of pro-IL-16 by immunoblotting and amino acid sequencing. Cleaved IL-16, but not pro-IL-16, exhibited lymphocyte chemoattractant activity. A C-terminal approximately 20-kDa IL-16 polypeptide was also released when pro-IL-16 was treated with concanavalin A-stimulated CD8(+) lymphocyte lysate. Cleavage occurred after an Asp, suggesting involvement of a caspase (interleukin-1beta-converting enzyme/CED-3) family protease. Using recombinant caspases and granzyme B, we determined that pro-IL-16 cleavage is mediated only by caspase-3. Relevance to pro-IL-16 processing in primary lymphocytes was supported by identifying the p20 subunit of activated caspase-3 in stimulated CD8(+) lymphocytes and by inhibition of CD8(+) lymphocyte lysate-mediated cleavage with Ac-DEVD-CHO. Pro-IL-16 is a substrate for caspase-3, and cleavage by this enzyme releases biologically active IL-16 from its inactive precursor.
Collapse
Affiliation(s)
- Y Zhang
- Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
| | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Interleukin-16 (IL-16) is a pro-inflammatory cytokine. It is synthesized as a precursor molecule that is processed by cleavage of a C-terminal 14 kDa peptide, which aggregates into bioactive tetramers. IL-16 requires the expression of CD4 for its functions, which include induction of chemotaxis, interleukin-2 receptor and HLA-DR expression, reversible inhibition of TcR/CD3-dependent activation and induction of a repressor of HIV-1 transcription. It represents a major source of the lymphocyte chemotactic activity early after antigen challenge of atopic asthmatics in which the major cell of origin is the epithelium, although mast cells, CD8 cells, CD4 cells and eosinophils are also sources; and the presence of IL-16 directly correlates with the number of infiltrating CD4+ T cells. Potential therapeutic applications are use of inhibitors of IL-16 in asthma and for IL-16 in selective CD4+ T cell immune reconstitution in HIV-1 infection or following chemotherapy.
Collapse
Affiliation(s)
- D M Center
- Pulmonary Center, Boston University School of Medicine, Evans Memorial Department of Medicine, MA 02118, USA
| | | | | |
Collapse
|
14
|
Abstract
PDZ (also called DHR or GLGF) domains are found in diverse membrane-associated proteins including members of the MAGUK family of guanylate kinase homologues, several protein phosphatases and kinases, neuronal nitric oxide synthase, and several dystrophin-associated proteins, collectively known as syntrophins. Many PDZ domain-containing proteins appear to be localised to highly specialised submembranous sites, suggesting their participation in cellular junction formation, receptor or channel clustering, and intracellular signalling events. PDZ domains of several MAGUKs interact with the C-terminal polypeptides of a subset of NMDA receptor subunits and/or with Shaker-type K+ channels. Other PDZ domains have been shown to bind similar ligands of other transmembrane receptors. Recently, the crystal structures of PDZ domains, with and without ligand, have been determined. These demonstrate the mode of ligand-binding and the structural bases for sequence conservation among diverse PDZ domains.
Collapse
Affiliation(s)
- C P Ponting
- University of Oxford, Fibrinolysis Research Unit, UK
| | | | | | | |
Collapse
|
15
|
Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med 1997; 3:659-64. [PMID: 9176493 DOI: 10.1038/nm0697-659] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Interleukin-16 (IL-16) is secreted by activated CD8+ T lymphocytes and acts on CD4+ T lymphocytes, monocytes and eosinophils. Recently, the C-terminal 130-amino acid portion of IL-16 was shown to suppress HIV-1 replication in vitro. To explore the potential of human IL-16 for gene therapy, this portion was transfected into HIV-1-susceptible CD4+ jurkat cells by means of a mammalian expression vector. The stable transfectants synthesized and secreted IL-16 protein. The expression of IL-16 did not alter growth rate and CD4 expression; however, HIV replication was inhibited by as much as 99%. Furthermore, during the initial phase of the infection, equal amounts of HIV-1 proviral DNA were found in cells transfected with IL-16 and with vector alone. In contrast, the 2-kilobase HIV-1 transcripts were markedly reduced and the 4-kb and 9-kb transcripts were undetectable in the cells transfected with IL-16. These findings indicate that IL-16-mediated inhibition of HIV-1 is not at the level of viral entry or reverse transcription, but at messenger RNA expression.
Collapse
Affiliation(s)
- P Zhou
- Branch of Oral Infection and Immunity, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | |
Collapse
|
16
|
Baier M, Bannert N, Werner A, Lang K, Kurth R. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci U S A 1997; 94:5273-7. [PMID: 9144227 PMCID: PMC24668 DOI: 10.1073/pnas.94.10.5273] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Interleukin 16 (IL-16) has been shown to function as chemoattractant factor, as a modulator of T-cell activation, and as an inhibitor of immunodeficiency virus replication. The recent identification of inconsistencies in published IL-16 cDNA nucleotide sequences led to the proposal that IL-16 is synthesized in the form of a large precursor protein (pro-IL-16). To identify the true transcriptional start of the IL-16 mRNA rapid amplification of cDNA ends methods were applied. The complete pro-IL-16 cDNA was subsequently molecularly cloned, sequenced, and expressed in COS-7 cells. We report here that pro-IL-16 is most likely synthesized as a 67-kDa protein and is encoded from a major 2.6-kb transcript. Recombinant pro-IL-16 polypeptides are specifically cleaved in lysates of CD8(+) cells, suggesting that the naturally secreted bioactive form of IL-16 is smaller than the originally published 130 amino acids fragment. Moreover, in contrast to other interleukins such as IL-15, IL-16 mRNA expression is almost exclusively limited to lymphatic tissues underlining the potential of IL-16 as an immune regulatory molecule.
Collapse
Affiliation(s)
- M Baier
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany.
| | | | | | | | | |
Collapse
|
17
|
|
18
|
|
19
|
|